Cargando…

Recent Advanced in the Treatment of Advanced SCC Tumors

SIMPLE SUMMARY: Suamous cell carcinoma (SCC) is the most frequent skin carcinoma after basal cell carcinoma. Advanced squamous cell carcinoma (aSCC) are tumors not treatable by surgery or radiotherapy. They represent a rare subgroup of SCC for which no standardized treatment has not been available a...

Descripción completa

Detalles Bibliográficos
Autores principales: Basset-Seguin, Nicole, Maubec, Eve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833343/
https://www.ncbi.nlm.nih.gov/pubmed/35158818
http://dx.doi.org/10.3390/cancers14030550
_version_ 1784648912531881984
author Basset-Seguin, Nicole
Maubec, Eve
author_facet Basset-Seguin, Nicole
Maubec, Eve
author_sort Basset-Seguin, Nicole
collection PubMed
description SIMPLE SUMMARY: Suamous cell carcinoma (SCC) is the most frequent skin carcinoma after basal cell carcinoma. Advanced squamous cell carcinoma (aSCC) are tumors not treatable by surgery or radiotherapy. They represent a rare subgroup of SCC for which no standardized treatment has not been available and chemotherapy was so far mostly palliative. Indeed, their prognosis was very poor. The development of immunotherapy has modified the outcome of such tumors. The rationale for immunotherapy for these tumors is the high mutational burden and their significant increase in incidence in immunosuppressed patients. This review aimed to present the definition of aSCC and discuss the different therapeutical options and treatment modalities. ABSTRACT: Squamous cell carcinoma (SCC) is the second most frequent form of skin cancer after basal cell carcinoma. While most SCC can be treated by surgery or radiotherapy, some progress into an advanced form and are no longer suitable for these treatments. Guidelines and staging systems have help to define these advanced SCC (aSCC), for which prognosis was very poor until recently. Platin-based chemotherapy was traditionally used, but few prospective trials and no treatment regimen was recommended. Furthermore, toxicity in elderly patients limited its use. The development of immunotherapy has improved the prognosis of these difficult-to-treat aSCC. In this review, we define high risk and aSCC and explored current treatment strategies for these tumors.
format Online
Article
Text
id pubmed-8833343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88333432022-02-12 Recent Advanced in the Treatment of Advanced SCC Tumors Basset-Seguin, Nicole Maubec, Eve Cancers (Basel) Commentary SIMPLE SUMMARY: Suamous cell carcinoma (SCC) is the most frequent skin carcinoma after basal cell carcinoma. Advanced squamous cell carcinoma (aSCC) are tumors not treatable by surgery or radiotherapy. They represent a rare subgroup of SCC for which no standardized treatment has not been available and chemotherapy was so far mostly palliative. Indeed, their prognosis was very poor. The development of immunotherapy has modified the outcome of such tumors. The rationale for immunotherapy for these tumors is the high mutational burden and their significant increase in incidence in immunosuppressed patients. This review aimed to present the definition of aSCC and discuss the different therapeutical options and treatment modalities. ABSTRACT: Squamous cell carcinoma (SCC) is the second most frequent form of skin cancer after basal cell carcinoma. While most SCC can be treated by surgery or radiotherapy, some progress into an advanced form and are no longer suitable for these treatments. Guidelines and staging systems have help to define these advanced SCC (aSCC), for which prognosis was very poor until recently. Platin-based chemotherapy was traditionally used, but few prospective trials and no treatment regimen was recommended. Furthermore, toxicity in elderly patients limited its use. The development of immunotherapy has improved the prognosis of these difficult-to-treat aSCC. In this review, we define high risk and aSCC and explored current treatment strategies for these tumors. MDPI 2022-01-22 /pmc/articles/PMC8833343/ /pubmed/35158818 http://dx.doi.org/10.3390/cancers14030550 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Basset-Seguin, Nicole
Maubec, Eve
Recent Advanced in the Treatment of Advanced SCC Tumors
title Recent Advanced in the Treatment of Advanced SCC Tumors
title_full Recent Advanced in the Treatment of Advanced SCC Tumors
title_fullStr Recent Advanced in the Treatment of Advanced SCC Tumors
title_full_unstemmed Recent Advanced in the Treatment of Advanced SCC Tumors
title_short Recent Advanced in the Treatment of Advanced SCC Tumors
title_sort recent advanced in the treatment of advanced scc tumors
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833343/
https://www.ncbi.nlm.nih.gov/pubmed/35158818
http://dx.doi.org/10.3390/cancers14030550
work_keys_str_mv AT bassetseguinnicole recentadvancedinthetreatmentofadvancedscctumors
AT maubeceve recentadvancedinthetreatmentofadvancedscctumors